In March 2025, the Food and Drug Administration added a rare, sudden form of vision loss to its list of potential serious risks for GLP-1 drugs and said it was "evaluating the need for regulatory action." Eighteen months later, the current U.S. prescribing information for Ozempic, Wegovy, Rybelsus, and Mounjaro still does not mention the condition, even as regulators in Europe, the United Kingdom, and Australia have issued warnings.
The condition is non-arteritic anterior ischemic optic neuropathy, or NAION, a loss of blood flow to the optic nerve that can permanently damage sight. For the millions of Americans taking these drugs, the gap raises a practical question about what patients are told and when.
